{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hamilton KW"],"funding":["NIAID NIH HHS"],"pagination":["ofae388"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11297503"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(8)"],"pubmed_abstract":["<h4>Background</h4>During the COVID-19 pandemic, SARS-CoV-2 monoclonal antibodies for preexposure prophylaxis (SMA-PrEP) offered patients who were immunocompromised another option for protection. However, SMA-PrEP posed administrative, operational, and ethical challenges for health care facilities, resulting in few patients receiving them. Although the first SMA-PrEP medication, tixagevimab and cilgavimab, had its authorization revoked due to compromised in vitro efficacy, new SMA-PrEP medications are currently completing clinical trials. This article provides an operational framework for administrative organization, patient identification and prioritization, equitable medication allocation, medication ordering and administration, and patient tracking.<h4>Methods</h4>A retrospective cohort"],"journal":["Open forum infectious diseases"],"pubmed_title":["Implementation of an Approach to Equitable Allocation of SARS-CoV-2 Monoclonal Antibodies for Preexposure Prophylaxis: Experience From a Single Medical Center."],"pmcid":["PMC11297503"],"funding_grant_id":["UM1 AI144288"],"pubmed_authors":["Fernandez Lynch H","Payne AS","Dutcher L","Takach P","Tebas P","Doucette AG","Craig E","Civitello T","Blumberg EA","Ahya VN","Degnan KO","Holzman L","Jacobs DA","Geara A","Hua E","Hamilton KW","Koenig H","Pratz K","Kannel EZ","Gabriel P","Werner D","Junker P","Garfall A","Capozzi D"],"additional_accession":[]},"is_claimable":false,"name":"Implementation of an Approach to Equitable Allocation of SARS-CoV-2 Monoclonal Antibodies for Preexposure Prophylaxis: Experience From a Single Medical Center.","description":"<h4>Background</h4>During the COVID-19 pandemic, SARS-CoV-2 monoclonal antibodies for preexposure prophylaxis (SMA-PrEP) offered patients who were immunocompromised another option for protection. However, SMA-PrEP posed administrative, operational, and ethical challenges for health care facilities, resulting in few patients receiving them. Although the first SMA-PrEP medication, tixagevimab and cilgavimab, had its authorization revoked due to compromised in vitro efficacy, new SMA-PrEP medications are currently completing clinical trials. This article provides an operational framework for administrative organization, patient identification and prioritization, equitable medication allocation, medication ordering and administration, and patient tracking.<h4>Methods</h4>A retrospective cohort","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2026-05-04T06:47:05.402Z","creation":"2025-02-19T04:40:33.832Z"},"accession":"S-EPMC11297503","cross_references":{"pubmed":["39100528"],"doi":["10.1093/ofid/ofae388"]}}